NASDAQ: LRMRLarimar Therapeutics Inc Stock
$3.66+0.16 (+4.57%)
Updated Jun 26, 2026
LRMR Price
$3.66
Fair Value Price
$1.12
Market Cap
$380.21M
52 Week Low
$2.72
52 Week High
$6.42
P/E
-1.74x
P/B
2.41x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$166.01M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.32
Operating Cash Flow
-$131M
Beta
1.18
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
LRMR Overview
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LRMR's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important LRMR news, forecast changes, insider trades & much more!
LRMR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LRMR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LRMR ($3.66) is overvalued by 228.22% relative to our estimate of its Fair Value price of $1.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LRMR ($3.66) is not significantly undervalued (228.22%) relative to our estimate of its Fair Value price of $1.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LRMR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LRMR due diligence checks available for Premium users.
Valuation
LRMR fair value
Fair Value of LRMR stock based on Discounted Cash Flow (DCF)
Price
$3.66
Fair Value
$1.12
Overvalued by
228.22%
LRMR ($3.66) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LRMR ($3.66) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LRMR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LRMR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.74x
Industry
16.11x
Market
12.38x
LRMR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.41x
Industry
5.36x
LRMR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LRMR's financial health
Profit margin
Revenue
$0.0
Net Income
-$29.6M
Profit Margin
0%
LRMR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$208.5M
Liabilities
$50.5M
Debt to equity
0.32
LRMR's short-term assets ($204.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LRMR's short-term assets ($204.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LRMR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LRMR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$44.6M
Investing
$29.0M
Financing
$108.1M
LRMR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LRMR vs Biotech Stocks
Larimar Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.